China Resources Boya Bio pharmaceutical Group Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 23.15%

China Resources Boya Bio pharmaceutical Group Co Ltd (300294) has an Asset Resilience Ratio of 23.15% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of China Resources Boya Bio pharmaceutical to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥1.95 Billion
≈ $284.73 Million USD Cash + Short-term Investments

Total Assets

CN¥8.41 Billion
≈ $1.23 Billion USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2025)

This chart shows how China Resources Boya Bio pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. See China Resources Boya Bio pharmaceutical (300294) net asset quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down China Resources Boya Bio pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of China Resources Boya Bio pharmaceutical .

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥1.95 Billion 23.15%
Total Liquid Assets CN¥1.95 Billion 23.15%

Asset Resilience Insights

  • Good Liquidity Position: China Resources Boya Bio pharmaceutical Group Co Ltd maintains a healthy 23.15% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

China Resources Boya Bio pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio

Compare China Resources Boya Bio pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Spyre Therapeutics Inc.
NASDAQ:SYRE
Biotechnology 84.34%
3SBio Inc
F:83B
Biotechnology 10.64%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 20.15%
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
Biotechnology 0.02%
Novavax Inc
NASDAQ:NVAX
Biotechnology 53.87%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for China Resources Boya Bio pharmaceutical Group Co Ltd (2015–2025)

The table below shows the annual Asset Resilience Ratio data for China Resources Boya Bio pharmaceutical Group Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 30.79% CN¥2.66 Billion
≈ $388.79 Million
CN¥8.63 Billion
≈ $1.26 Billion
+4.61pp
2024-12-31 26.18% CN¥2.20 Billion
≈ $321.80 Million
CN¥8.40 Billion
≈ $1.23 Billion
-16.77pp
2023-12-31 42.95% CN¥3.36 Billion
≈ $492.03 Million
CN¥7.83 Billion
≈ $1.15 Billion
+3.19pp
2022-12-31 39.76% CN¥3.19 Billion
≈ $467.37 Million
CN¥8.03 Billion
≈ $1.18 Billion
+4.33pp
2021-12-31 35.42% CN¥2.70 Billion
≈ $395.09 Million
CN¥7.62 Billion
≈ $1.12 Billion
+33.36pp
2016-12-31 2.07% CN¥50.00 Million
≈ $7.32 Million
CN¥2.42 Billion
≈ $354.05 Million
+1.15pp
2015-12-31 0.91% CN¥20.00 Million
≈ $2.93 Million
CN¥2.19 Billion
≈ $320.20 Million
--
pp = percentage points

About China Resources Boya Bio pharmaceutical Group Co Ltd

SHE:300294 China Biotechnology
Market Cap
$1.16 Billion
CN¥7.91 Billion CNY
Market Cap Rank
#8440 Global
#2074 in China
Share Price
CN¥15.68
Change (1 day)
-1.32%
52-Week Range
CN¥15.32 - CN¥27.54
All Time High
CN¥55.20
About

China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China. It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound b… Read more